Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy.
BACKGROUND
The most common site of metastases in differentiated thyroid carcinomas is the lungs. In our study, we aimed to determine the ratios of lung metastases in patients with differentiated thyroid carcinoma and response to radioiodine therapy.


METHODS
A total of 542 patients with differentiated thyroid carcinoma who were admitted to our clinic were included in the study. High doses of (131)I were administered to the patients with lung metastases. Response to therapy were evaluated with (131)I scans and stimulated serum Tg levels were examined at least 6 months after therapy.


RESULTS
Lung metastases were detected in 17 (3.1%) of 542 patients with differentiated thyroid carcinoma. Of these patients to whom high doses of (131)I therapy were administered, complete response to therapy was obtained in 5 (29.4%), partial response was obtained in 3 (17.6%) and no response could be obtained in 9 (53%) patients.


CONCLUSIONS
Although lung metastases from differentiated thyroid carcinomas are rare, those are more common in advanced ages and in males. High doses of (131)I therapy may be partially beneficial in these patients. Thus repetition of therapy is frequently required.
Gaziantep University Medicine School, Department of Nuclear Medicine, Gaziantep, Turkey.
E
E
Kalender
Y
Y
Zeki Celen
U
U
Elboga
H
H
Deniz Demir
M
M
Yilmaz
D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002291:Carcinoma, Papillary / Q000097:blood / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D008297:Male; D015995:Prevalence; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D012074:Remission Induction; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery; D013965:Thyroidectomy; D016896:Treatment Outcome; D051598:Whole Body Imaging; D055815:Young Adult
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D013954:Thyroglobulin